Translational Program
In order to advance potential drugs into clinical trials, a panel of tests are required before an Investigatory New Drug (IND) application can be submitted to the FDA.The Institute for Drug Discovery has assisted faculty in their endeavors to translate their drugs into the clinic by providing assistance to perform some of these IND-enabling studies and performing the clinical trials themselves.
2024 Translational Awards and Clinical Trial Support
| Faculty | Project Description |
| Zhong-Yin Zhang | Pre-clinical development of a first-in-class, potent, and selective SHP1 covalent inhibitor for cancer immunotherapy |
| Stephen Byrn | Solid Lipid Nanoparticle Delivery of Etoposide Phosphate |
| Herman Sintim | TAK-1 kinase inhibitors |
2023 Translational Awards and Clinical Trial Support
| Faculty | Project Description |
| Riyi Shi | Small Molecule Reactive Aldehyde Scavengers for Spinal Cord and Neurotrauma |
| P.V. Ramachandran | Pre-clinical development of a potent, lead molecule to treat Clostridiodes difficile infection |
| Phil Low | Tanzania and Kenya Malaria/Sickle Cell clinical trial planning |
2022 Translational Awards and Clinical Trial Support
| Faculty | Project Description |
| Phil Low | Vietnam Phase 3 adult malaria clinical trial planning |
2019 Translational Awards and Clinical Trial Support
| Faculty | Project Description |
| Phil Low | IUSM and Cincinnati Children's Hospital sickle cell trial support |
2015-2016 Translational Awards and Clinical Trial Support
| Faculty | Project Description |
| Phil Low | Vietnam Phase 2 malaria trial support |